[go: up one dir, main page]

WO2002007733A3 - Method for enhancing bone mineral density gain by administration of raloxifene - Google Patents

Method for enhancing bone mineral density gain by administration of raloxifene Download PDF

Info

Publication number
WO2002007733A3
WO2002007733A3 PCT/US2001/016515 US0116515W WO0207733A3 WO 2002007733 A3 WO2002007733 A3 WO 2002007733A3 US 0116515 W US0116515 W US 0116515W WO 0207733 A3 WO0207733 A3 WO 0207733A3
Authority
WO
WIPO (PCT)
Prior art keywords
raloxifene
mineral density
bone mineral
administration
density gain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/016515
Other languages
French (fr)
Other versions
WO2002007733A2 (en
Inventor
Douglas Boyer Muchmore
Yili Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to JP2002513468A priority Critical patent/JP2004504351A/en
Priority to US10/332,179 priority patent/US20030216358A1/en
Priority to EP01952124A priority patent/EP1307206A2/en
Priority to CA002412373A priority patent/CA2412373A1/en
Priority to AU2001272916A priority patent/AU2001272916A1/en
Priority to AU7291601A priority patent/AU7291601A/en
Publication of WO2002007733A2 publication Critical patent/WO2002007733A2/en
Anticipated expiration legal-status Critical
Publication of WO2002007733A3 publication Critical patent/WO2002007733A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a method for enhancing bone mineral density gain acquired through previous bisphosphonate therapy comprising administering to a human in need thereof a bone-enhancing amount of raloxifene or a pharmaceutically acceptable salt or solvate thereof.
PCT/US2001/016515 2000-07-19 2001-07-05 Method for enhancing bone mineral density gain by administration of raloxifene Ceased WO2002007733A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002513468A JP2004504351A (en) 2000-07-19 2001-07-05 How to increase bone mass
US10/332,179 US20030216358A1 (en) 2001-07-05 2001-07-05 Method for enhancing bone mineral density gain
EP01952124A EP1307206A2 (en) 2000-07-19 2001-07-05 Method for enhancing bone mineral density gain by administration of raloxifene
CA002412373A CA2412373A1 (en) 2000-07-19 2001-07-05 Method for enhancing bone mineral density gain
AU2001272916A AU2001272916A1 (en) 2000-07-19 2001-07-05 Method for enhancing bone mineral density gain by administration of raloxifene
AU7291601A AU7291601A (en) 2000-07-19 2001-07-07 Method for enhancing bone mineral density gain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21928600P 2000-07-19 2000-07-19
US60/219,286 2000-07-19
US23373700P 2000-09-19 2000-09-19
US60/233,737 2000-09-19

Publications (2)

Publication Number Publication Date
WO2002007733A2 WO2002007733A2 (en) 2002-01-31
WO2002007733A3 true WO2002007733A3 (en) 2003-02-06

Family

ID=26913746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016515 Ceased WO2002007733A2 (en) 2000-07-19 2001-07-05 Method for enhancing bone mineral density gain by administration of raloxifene

Country Status (5)

Country Link
EP (1) EP1307206A2 (en)
JP (1) JP2004504351A (en)
AU (2) AU2001272916A1 (en)
CA (1) CA2412373A1 (en)
WO (1) WO2002007733A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360619B2 (en) * 2001-12-21 2006-10-05 Allergan Pharmaceuticals International Limited Method for the treatment of bone disorders
CA2529558A1 (en) * 2003-07-01 2005-01-13 Astellas Pharma Inc. Agent inducing increase in bone mass
KR100557086B1 (en) * 2003-11-14 2006-03-03 한미약품 주식회사 Mutual Salts of Raloxifene and Bisphosphonates
JP2007523184A (en) * 2004-02-19 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド Improved therapy using a combination of raloxifene and alendronate
JP2008120702A (en) * 2006-11-09 2008-05-29 Pola Chem Ind Inc Oral administration composition for arthritis/arthrosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693285A2 (en) * 1994-07-22 1996-01-24 Eli Lilly And Company Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693285A2 (en) * 1994-07-22 1996-01-24 Eli Lilly And Company Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
N.B.WATTS: "Treatment of osteoporosis with biophosphonates", RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, vol. 27, no. 1, 2001, pages 197 - 214, XP008008277 *
P.BURCKHARDT: "Selective estrogen receptor modulators (SERM): neue Substanzen für die Hormonersatztherapie", SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, vol. 129, no. 49, 1999, pages 1926 - 1930, XP000937653 *

Also Published As

Publication number Publication date
CA2412373A1 (en) 2002-01-31
AU7291601A (en) 2002-02-05
EP1307206A2 (en) 2003-05-07
AU2001272916A1 (en) 2002-02-05
WO2002007733A2 (en) 2002-01-31
JP2004504351A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
PL366430A1 (en) Sustained release formulations of oxymorphone
MY134190A (en) Compositions and methods for stimulating gastrointestinal motility.
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CY1107813T1 (en) HYDROMORPHONE, DIHYDROMORPHINE AND DIAHRODROMORPHINE SUGAR PRODUCTS
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
HUP0301164A3 (en) Method of administering bisphosphonates
EP1708685A4 (en) Effervescent oral opiate dosage forms and methods of administering opiates
BG105459A (en) Pharmaceutical moxifloxacin preparation
PT998287E (en) USES OF LEVOBUPIVACAINE
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
CY1106763T1 (en) PREVENTIVE OR THERAPEUTIC MEANS FOR INFLAMMATORY BOWEL DISEASES
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2004058235A3 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
WO2001089494A3 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
EP1372571A4 (en) Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
WO2002007733A3 (en) Method for enhancing bone mineral density gain by administration of raloxifene
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
GB9930077D0 (en) Medicaments
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine
WO2002015894A3 (en) Use of vitamin d derivatives as bone resorption inhibitors
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
SI1591122T1 (en) Method of administering bisphosphonates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2412373

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 513468

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10332179

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001952124

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001952124

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2003131400

Country of ref document: RU

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 2001952124

Country of ref document: EP